Biosimilars | Association for Accessible Medicines


AAM's Christine Simmon Talks About Biosimilar Programming at GRx+Biosims 2019

I’m Christine Simmon, Senior Vice President of Policy and Executive Director of the Biosimilars Council at the Association for Accessible Medicines.

Working in this sector, I know how it feels to be inundated with invites to conferences and seminars and workshops and webinars -- all of which are supposed to help you stay on top of biosimilars. It’s a lot!

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights.

NAFTA 2.0: Obstacles to More Affordable Medicines

NAFTA 2.0 (USMCA) will keep drug prices out of reach for American patients.

Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.

The U.S.-Mexico-Canada Agreement (USMCA), the update to the North America Free Trade Agreement (NAFTA), contains provisions that will: 

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

WASHINGTON, DC (March 7, 2019) – “AAM is reviewing the FDA’s new draft guidance on biosimilar naming requirements and will submit comments to the docket. FDA’s current requirement of suffixes presents a significant, artificial barrier to biosimilars that is misaligned with the agency’s own Biosimilars Action Plan and the Trump administration’s commitment to lowering drug prices for America’s patients.”

Christine Simmon: GRx+Biosims Combines Three Events into One

Christine Simmon, AAM Senior Vice President of Policy and Strategic Alliances and Executive Director of the Biosimilars Council, invites industry professionals to attend GRx+Biosims 2018 on Sept. 5-7 in Baltimore, MD. This year, we are combining FallTech, Leading on Biosimilars, and CMC Workshop to one can't-miss opportunity to connect with peers around the world.

Subscribe to Biosimilars

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.